Scientists at Atmosr SAS and Medetia SAS have synthesized adenine derivatives acting as heat shock protein 90 (HSP90) inhibitors reported to be useful for the treatment of cancer, neurodegenerative diseases, infections, myelofibrosis, acute pancreatitis, psoriasis and ROHHAD (rapid-onset obesity, hypothalamic dysfunction, hypoventilation, autonomic dysregulation).